Faron has initiated development of GMP manufacturing of the humanized anti-Clever-1 antibody FP-1304 with Biovian

The FPCLI001 clinical trial with FP-1201 in acute lung injuries has been completed: also the long-term secondary end point demonstrates a significant decrease in mortality

Faron reports positive headline data from FPCLI001 clinical study with FP- 1201 in acute lung injuries

FPCLI001 trial treating acute lung injury with FP-1201 has completed recruitment